Cabot (CBT)
(Delayed Data from NYSE)
$109.02 USD
+1.19 (1.10%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $109.06 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$109.02 USD
+1.19 (1.10%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $109.06 +0.04 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Here's Why You Should Buy Eastman Chemical (EMN) Stock Right Now
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions, operational execution and innovation.
Why Should You Add Air Products (APD) Stock to Your Portfolio
by Zacks Equity Research
Air Products (APD) benefits from its investments in high-return industrial gas projects, project wins and productivity initiatives.
Cabot (CBT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cabot (CBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Cabot (CBT) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.
CBT or AIQUY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBT vs. AIQUY: Which Stock Is the Better Value Option?
Is Cabot (CBT) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Hawkins (HWKN) Up 51% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Hawkins (HWKN) benefits from the robust Water Treatment segment, strategic acquisitions and a prudent pricing strategy.
CBT or AIQUY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBT vs. AIQUY: Which Stock Is the Better Value Option?
Is Cabot (CBT) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Cabot (CBT) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cabot (CBT) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Why Cabot (CBT) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.
Here's Why Cabot (CBT) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cabot (CBT) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cabot (CBT) have what it takes? Let's find out.
Should Value Investors Buy Cabot (CBT) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cabot (CBT) Unveils REPLASBLAK Masterbatch Product Family
by Zacks Equity Research
Cabot's (CBT) newly released EVOLVE Sustainable Solutions technology platform is intended to create products with sustainable content and dependable performance at an industrial scale.
Cabot's (CBT) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
The decline in sales of Cabot's (CBT) Reinforcement Materials unit is due to reduced sales in the Americas and EMEA in the fiscal fourth quarter.
Cabot (CBT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Cabot (CBT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -16.88% and 3.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
CBT vs. AIQUY: Which Stock Is the Better Value Option?
by Zacks Equity Research
CBT vs. AIQUY: Which Stock Is the Better Value Option?
Stepan Co. (SCL) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Stepan Co. (SCL) delivered earnings and revenue surprises of -15.79% and 6.88%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Cabot (CBT) Boosts Circularity & Traceability With ISCC PLUS
by Zacks Equity Research
Cabot's (CBT) ISCC PLUS certified facilities adhere to ISCC PLUS requirements by leveraging circular value chains and certified feedstocks in the product manufacturing process.
Why Is Cabot (CBT) Up 2.2% Since Last Earnings Report?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) Joins US Energy Department's Better Plants Program
by Zacks Equity Research
Cabot (CBT) believes that this engagement with the DOE will help the company boost its energy efficiency performance.